Crown Laboratories and Revance Therapeutics have announced a merger agreement under which Crown Laboratories will acquire all outstanding shares of Revance Therapeutics’ stock for $6.66 per share in cash, valuing the deal at a total enterprise value of $914 million. This acquisition is expected to close by the end of the year and will result in a combined company with an industry-leading portfolio of over 10 skin health and aesthetic brands.
Strategic Expansion in Aesthetics and Skin Care
The merger will significantly expand Crown Laboratories’ presence in the global aesthetics and skin care market. Jeff Bedard, the Founder and CEO of Crown, highlighted that the acquisition is a major milestone in Crown’s journey to becoming a fully integrated global leader in aesthetics and skin care. He noted that Revance’s innovative aesthetic products are a perfect complement to Crown’s existing portfolio, positioning the combined company to offer a comprehensive range of high-growth products designed for all stages of life.
Commitment to Education and Provider Support
Bedard also emphasized that the merger will enhance the company’s ability to invest in education, training, and practice support for aesthetics providers across the United States. By integrating Revance’s expertise with Crown’s extensive distribution network across medical, retail, and e-commerce channels, the merged entity aims to strengthen its leadership position in the skin care industry and deliver innovative solutions to consumers and professionals alike.
Related topics:
